Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4108 Target Snapshot

Voltage-dependent L-type calcium channel subunit alpha-1S · SINGLE PROTEIN · Rattus norvegicus

36Compounds
4Assays
1Approved Drugs
40.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q02485. Use UniProt Q02485 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q02485 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Voltage-dependent L-type calcium channel subunit alpha-1S as ChEMBL target CHEMBL4108, mapped to UniProt Q02485. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Voltage-dependent L-type calcium channel subunit alpha-1S
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL4108
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q02485
Voltage-dependent L-type calcium channel subunit alpha-1S
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Voltage-dependent L-type calcium channel subunit alpha-1S is the right protein anchor across sources, using UniProt Q02485 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelVoltage-dependent L-type calcium channel subunit alpha-1S
UniProt AccessionQ02485
Component TypeProtein
Sequence Length1850 aa

Voltage-dependent L-type calcium channel subunit alpha-1S

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Voltage-dependent L-type calcium channel subunit alpha-1S, mapped to UniProt Q02485. Sequence length is 1850 aa.

Mapped IDQ02485
Review nameVoltage-dependent L-type calcium channel subunit alpha-1S
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

IC506.0
KI34.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL599337 9.38 IC50 0.42 Preclinical
CHEMBL592155 9.12 IC50 0.76 Preclinical
CHEMBL335742 8.3 Ki 5.0 Preclinical
CHEMBL599336 8.09 IC50 8.14 Preclinical
CHEMBL334400 7.92 Ki 12.0 Preclinical
CHEMBL341462 7.34 Ki 46.0 Preclinical
CHEMBL134195 7.32 Ki 48.0 Preclinical
CHEMBL6966 7.24 Ki 58.0 Approved
CHEMBL130086 7.21 Ki 62.0 Preclinical
CHEMBL132844 7.21 Ki 62.0 Preclinical
Distribution

pChEMBL Value Distribution

1
5.0
1
5.5
13
6.0
6
6.5
11
7.0
2
7.5
3
8.0
1
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

VERAPAMIL
CHEMBL6966
Approved 1981
Assay Landscape

Assay Landscape

4
Total Assays
36
Tested Compounds
1
Assay Types
Binding — 4 assays, 36 compounds
BAO Format Assays Compounds Avg pChEMBL
cell membrane format 2 3 8.6
tissue-based format 2 33 6.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine